Role of SCT in CR1. Simon-Makuch plots for RFS (A) and OS (B) in CR patients. t0 was the time of hematologic CR achievement. RFS and OS were significantly prolonged in the allogeneic SCT cohort (HR, 0.69 [95% CI, 0.49-0.98; P = .036] and 0.64 [95% CI, 0.44-0.93; P = .020], respectively, by the Andersen-Gill test). Simon-Makuch plots for RFS (C) and OS (D) in patients in MMolR at MRD2 time point. t0 was the time of MRD2 MMolR achievement. RFS and OS were similar in the autologous and allogeneic SCT cohorts (HR, 0.94 [95% CI, 0.53-1.65; P = .82] and 0.95 [95% CI, 0.51-1.74; P = .86], respectively, by the Andersen-Gill test). A 3-month RFS landmark period (median time from CR to transplantation) was used, because patients should be alive but also in CR1 to be actually transplanted. This landmark allowed minimizing the bias related to early relapses when comparing OS with this method.